Results 361 to 370 of about 327,068 (394)

Real‐life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype

Clinical and Experimental Allergy, 2020
Anti‐interleukin‐5 (IL‐5) monoclonal antibodies can be used as add‐on biological therapies in allergic and non‐allergic patients with severe eosinophilic asthma. However, within such a therapeutic context real‐life investigations are lacking.
C. Pelaia, C. Crimi, G. Pelaia, S. Nolasco, R. Campisi, E. Heffler, G. Valenti, N. Crimi   +7 more
semanticscholar   +1 more source

“Refractory” Eosinophilic Airway Inflammation in Severe Asthma

American Journal of Respiratory and Critical Care Medicine, 2004
It has been suggested that patients with refractory eosinophilic airway inflammation represent a separate “eosinophilic” asthma phenotype associated with increased morbidity and a poor prognosis. To investigate whether persistent eosinophilia in these patients is a fixed feature or can still be modified by treatment, we investigated the effect of high ...
Anneke ten Brinke, Aeilko H. Zwinderman, Peter J. Sterk, Klaus F. Rabe, Elisabeth H. Bel   +4 more
openaire   +2 more sources

Reslizumab in the Treatment of Severe Eosinophilic Asthma: an Update

Immunotherapy, 2018
A marked heterogeneity is exhibited by asthma both clinically and at the molecular level with different phenotypes driven by diverse mechanistic pathways that require specifically targeted treatments. Biologics aimed at IL-4/13, IL-5 or IgE are proven or potentially effective treatments for patients with difficult to treat eosinophilic asthma ...
openaire   +2 more sources

Biological treatment is approved for severe eosinophilic asthma

BMJ, 2016
Draft guidance from the National Institute for Health and Care Excellence (NICE) recommends the monoclonal antibody mepolizumab as an option to treat adult patients with severe refractory asthma and raised eosinophil levels.1 The decision follows an agreement by the manufacturer, GlaxoSmithKline (GSK), to reduce the price of the drug—which has a list ...
openaire   +3 more sources

Primary lysis of eosinophils in severe desquamative asthma

Clinical & Experimental Allergy, 2014
SummaryPrimary lysis of eosinophils liberates free eosinophil granules (FEGs) releasing toxic proteins in association with bronchial epithelial injury repair. Eosinophil lysis may be significantly pathogenic. Bronchial mucosal FEGs are associated with uncontrolled asthma, severe asthma, aspirin‐sensitive asthma, and lethal asthma. FEGs in the bronchial
openaire   +3 more sources

BIOLOGICS SWITCH IN SEVERE EOSINOPHILIC ASTHMA

Airway pharmacology and treatment, 2021
Caminati, Marco, Guarnieri, Gabriella, Bagnasco, Diego, Chieco Bianchi, Fulvia, Carpagnano, Elisiana, Maule, Matteo, Molena, Beatrice, Pelaia, Girolamo, Pini, Laura, Senna, Gianenrico, Vianello, Andrea, Crisafulli, Ernesto   +11 more
openaire   +2 more sources

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

The Lancet, 2012
I. Pavord, Stephanie Korn, P. Howarth, E. Bleecker, R. Buhl, O. Keene, Hector Ortega, P. Chanez   +7 more
semanticscholar   +1 more source

Emerging Therapies in Severe Eosinophilic Asthma

Archivos de Bronconeumología (English Edition), 2017
Pee Hwee Pang, Christopher E. Brightling, Christopher E. Brightling   +2 more
openaire   +3 more sources

Critical care management of chimeric antigen receptor T‐cell therapy recipients

Ca-A Cancer Journal for Clinicians, 2022
Alexander Shimabukuro-vornhagen, Victoria Metaxa, Elie Azoulay   +2 more
exaly  

Real World Effectiveness of Benralizumab in Severe Eosinophilic Asthma.

Chest, 2020
J. Kavanagh, A. Hearn, J. Dhariwal, G. D'ancona, A. Douiri, C. Roxas, M. Fernandes, L. Green, L. Thomson, A. Nanzer, B. Kent, D. Jackson   +11 more
semanticscholar   +1 more source